The cardiovascular safety of oral alitretinoin: a population-based cohort study involving 19 513 patients exposed to oral alitretinoin.

Florence PoizeauF BalussonA P Jonville-BéraE NowakM D DriciP Y ScarabinCatherine DroitcourtA DupuyE Oger

Published in: The British journal of dermatology (2021)

These data from an exhaustive nationwide population-based study do not support an increase in the incidence of atherothrombotic events with alitretinoin use, regardless of the baseline cardiovascular risk of the patient.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
risk factors
prognostic factors
case report
electronic health record
machine learning
patient reported outcomes
patient reported